


Science in the Service of Medicine

Unique Targets.
Novel Mechanisms.
New Medicines.

Forward Looking Statement


To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of our Phase 2 SIGNAL trial of pepinemab (VX15/2503) in Huntington’s disease and other clinical trials, the use and potential benefits of pepinemab in Huntington’s disease and other indications, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the impact of the COVID-19 pandemic, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K dated March 9, 2020 and subsequent filings with the SEC.

Brain Cells Respond to Damage Induced by Mutant Huntingtin Protein




SEMA4D is progressively upregulated in neurons during HD progression

Q175 transgenic mouse model of HD




SIGNAL Clinical Trial Design – Early Manifest HD (TFC 11-13)



Clinical Global Impression of Change - CGIC

Early Manifest HD


Baseline UHDRS TFC 11 - 13




Clinical Global Impression of Change - CGIC

Subgroup Analysis— Early Manifest HD

Baseline UHDRS TFC 11




Baseline UHDRS TFC 12 and 13



- Very much worse
- Much worse
- Minimally worse
- No change
- Minimally improved
- Much improved


Σ
Δ
Φ
Ψ
Π
Θ
Ω

Assessment of Executive Function – Planning and Memory



Cognitive Assessment – Early Manifest HD

Co-Primary 2a: Planning and Memory




One-sided p-value	Favors PEPI	Success [Critical value]
0.028	Yes	No [0.025] [0.0125]

Difference (PEPI – PBO)

Change from Baseline at Month 17 (95% CI) = -1.98 (-4.00, 0.05)

Cognitive Assessment – Early Manifest HD

Co-Primary 2b: Paced Tapping (PTAP)




One-sided p-value	Favors PEPI	Success [Critical value]
0.06	Yes	No [0.025] [0.0125]

Difference (PEPI – PBO)

Change from Baseline at Month 17 (95% CI) = 1.43 (-0.37, 3.23)

HD-CAB Index of 6 Assessments – Early Manifest HD



One-sided p-value	Favors PEPI	Critical value
0.007	Yes	Yes [0.025]